Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
captopril + pentoxifylline
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of captopril, an angiotensin-converting enzyme (ACE) inhibitor, and pentoxifylline, a hemorheological agent. This combination has been studied primarily for its effects on proteinuria in diabetic nephropathy and for potential synergistic effects in hypertension treatment. Captopril works by inhibiting the conversion of angiotensin I to angiotensin II, while pentoxifylline improves blood flow properties by decreasing blood viscosity, increasing erythrocyte flexibility, and providing anti-inflammatory effects.
02
Targets
ADORA2A (Adenosine A₂A Receptor)ACE (Angiotensin Converting Enzyme)LCN2 (Lipocalin-2)MMP9 (Matrix metalloproteinase-9)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on captopril + pentoxifylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on captopril + pentoxifylline.